Cadila Pharmaceuticals Limited — Ketorolac Exporter Profile
Indian Pharmaceutical Exporter · #14 for Ketorolac · $570.3K export value · DGFT Verified
Cadila Pharmaceuticals Limited is the #14 Indian exporter of Ketorolac with $570.3K in export value and 56 verified shipments. Cadila Pharmaceuticals Limited holds a 0.5% market share in Ketorolac exports across 8 countries. The company exports 15 pharmaceutical products worth $20.2M across 11 therapeutic categories.
Cadila Pharmaceuticals Limited — Ketorolac Export Profile: Buyers & Destinations
Where Does Cadila Pharmaceuticals Limited Export Ketorolac?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RUSSIA | $486.5K | 26 | 82.3% |
| MAURITIUS | $24.7K | 13 | 4.2% |
| IRAQ | $22.6K | 1 | 3.8% |
| LATVIA | $20.5K | 1 | 3.5% |
| KYRGYZSTAN | $9.3K | 1 | 1.6% |
| GHANA | $8.2K | 3 | 1.4% |
| KYRGHYSTAN | $6.6K | 3 | 1.1% |
| KENYA | $5.2K | 6 | 0.9% |
| UGANDA | $4.0K | 2 | 0.7% |
| NIGERIA | $3.0K | 1 | 0.5% |
Cadila Pharmaceuticals Limited exports Ketorolac to 10 countries. The largest destination is RUSSIA accounting for 82.3% of Cadila Pharmaceuticals Limited's Ketorolac shipments, followed by MAURITIUS (4.2%) and IRAQ (3.8%). These destinations reflect Cadila Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ketorolac from Cadila Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| OOO CADILA PHARMACEUTICALS RUS LIMI | RUSSIA | $413.6K | 22 |
| OOO CADILA PHARMACEUTICALS RUS | RUSSIA | $45.0K | 2 |
| OOO CADILA PHARMACEUTICALS RUS LIMITED | RUSSIA | $27.9K | 2 |
| AL ZAWRAA SCIENTIFIC BUREAU DISTRICT | IRAQ | $22.6K | 1 |
| OOO CADILA PHARMACEUTICALS RUS LTD | LATVIA | $20.5K | 1 |
| HB CO LTD | KYRGHYSTAN | $16.0K | 4 |
| FTM (MAURITIUS) LIMITED | MAURITIUS | $11.0K | 3 |
| FTM (MAURITIUS) LTD | MAURITIUS | $8.9K | 6 |
| UNICHEM GHANA LIMITED | GHANA | $7.8K | 2 |
| CADILA PHARMACEUTICALS (E.A.) LTD | KENYA | $4.7K | 2 |
Cadila Pharmaceuticals Limited supplies Ketorolac to 16 buyers globally. The largest buyer is OOO CADILA PHARMACEUTICALS RUS LIMI (RUSSIA), followed by OOO CADILA PHARMACEUTICALS RUS (RUSSIA) and OOO CADILA PHARMACEUTICALS RUS LIMITED (RUSSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ketorolac Export Value and How Much Does Cadila Pharmaceuticals Limited Contribute?
India exported $49.5M worth of Ketorolac through 2,961 shipments from 351 suppliers to 124 countries, serving 638 buyers globally. Cadila Pharmaceuticals Limited contributes $570.3K to this total, accounting for 0.5% of India's Ketorolac exports. Cadila Pharmaceuticals Limited ships Ketorolac to 10 countries through 16 buyers.
What Is the Average Shipment Value for Cadila Pharmaceuticals Limited's Ketorolac Exports?
Cadila Pharmaceuticals Limited's average Ketorolac shipment value is $10.2K per consignment, based on 56 shipments totaling $570.3K. The largest destination is RUSSIA (82.3% of Cadila Pharmaceuticals Limited's Ketorolac exports).
How Does Cadila Pharmaceuticals Limited Compare to Other Indian Ketorolac Exporters?
Cadila Pharmaceuticals Limited ranks #14 among 351 Indian Ketorolac exporters with a 0.5% market share. The top 3 exporters are CAPLIN STERILES LIMITED ($11.5M), GLAND PHARMA LIMITED ($10.6M), GLAND PHARMA LTD ($9.7M). Cadila Pharmaceuticals Limited processed 56 shipments to 8 destination countries.
What Ketorolac Formulations Does Cadila Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHA DRG & MED DOLAC 30MG INJECTION CONT.KETOROLAC TROMETHAMINE QTY. 10PC/PAC | $68.1K | 4 |
| DOLAC 30MG INJECTION (R/M : KETOROLAC TR | $48.6K | 1 |
| DOLAC 30MG INJECTION R/M : KETOROLAC TR | $47.1K | 1 |
| DOLAC 30MG INJECTION (R/M : KETOROLAC TROMETHAMINE) BATCH EI059E4001 TO EI059E4006 MFG DT-FEB-2024 EXP DT-JAN-2027 | $44.4K | 1 |
| DOLAC 30MG TABLET (RM:KETOROLAC TROMETHA | $40.4K | 1 |
| DOLAC 30MG INJECTION (R/M : KETOROLAC TROMETHAMINE) BATCH EI059E4024 TO EI059E4028 Mfg Dt-NOV-2024 Exp Dt-OCT-2027 | $39.6K | 1 |
| DOLAC 30MG INJECTION (R/M : KETOROLAC TROMETHAMINE) BATCH EI059E5004 TO EI059E5006 Mfg Dt-FEB-2025 Exp Dt-JAN-2028 | $28.4K | 1 |
| DOLAC 30MG INJECTION (R/M : KETOROLAC TROMETHAMINE) BATCH EI059E5001 TO EI059E5003 Mfg Dt-FEB-2025 Exp Dt-JAN-2028 | $28.2K | 1 |
| DOLAC 30 10 X 1 ML AMP RM: KETOROLAC TROMETHAMINE USP B.NO.EI123E3001 | $22.6K | 1 |
| DOLAC 30MG TABLET (R/M : KETOROLAC TROMETHAMINE) BATCH EI059E3028 TO EI059E3030MFG DT-OCT-2023 EXP DT-SEP-2026 | $22.3K | 1 |
Cadila Pharmaceuticals Limited exports 44 distinct Ketorolac formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHA DRG & MED DOLAC 30MG INJECTION CONT.KETOROLAC TROMETHAMI with 4 shipments worth $68.1K.
How Does Cadila Pharmaceuticals Limited Compare to Nearest Ketorolac Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | PROTECH BIO SYSTEMS PRIVATE LIMITED | $598.5K | 73 | 2 | $8.2K |
| 13 | SCOTT EDIL PHARMACIA LIMITED | $576.3K | 32 | 6 | $18.0K |
| 14 | CADILA PHARMACEUTICALS LIMITED ★ | $570.3K | 56 | 8 | $10.2K |
| 11 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED | $400.0K | 8 | 1 | $50.0K |
| 15 | APEX LABORATORIES PRIVATE LIMITED | $350.0K | 7 | 1 | $50.0K |
Cadila Pharmaceuticals Limited ranks #14 among 351 Indian Ketorolac exporters. Average shipment value of $10.2K compared to the market average of $141.1K. The closest competitors by value are PROTECH BIO SYSTEMS PRIVATE LIMITED and SCOTT EDIL PHARMACIA LIMITED.
Which Indian Ports Ship Ketorolac Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 337 | 11.4% |
| SAHAR AIR | 229 | 7.7% |
| NHAVA SHEVA SEA (INNSA1) | 227 | 7.7% |
| HYDERABAD ICD (INSNF6) | 127 | 4.3% |
| HYDERABAD AIR | 93 | 3.1% |
| DELHI AIR | 92 | 3.1% |
| DELHI AIR CARGO ACC (INDEL4) | 75 | 2.5% |
| HYDERABAD ICD | 74 | 2.5% |
Geopolitical & Trade Policy Impact on Cadila Pharmaceuticals Limited's Ketorolac Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cadila Pharmaceuticals. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, causing major carriers to suspend or reroute transits. This has resulted in extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the timely delivery of pharmaceuticals. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. However, the U.S. has also implemented tariffs on Active Pharmaceutical Ingredients (APIs), leading to a reshoring of manufacturing and affecting Indian firms. In response, some Indian companies have invested in U.S. facilities to circumvent these tariffs. (odrindia.in)
In the European Union, compliance with the Falsified Medicines Directive (FMD) has become imperative. Indian exporters must ensure stringent adherence to these regulations to maintain market access, necessitating investments in serialization and traceability systems.
Cadila Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is crucial for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has previously issued warnings to Cadila Pharmaceuticals regarding deviations from standard manufacturing practices. (business-standard.com) To address such concerns, the company has invested in enhancing its quality control systems and manufacturing processes. Additionally, Cadila has engaged in legal proceedings concerning biosimilar approvals, highlighting the complexities of regulatory compliance in the biosimilars market. (legaleraonline.com)
About Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited exports 15 products worth $20.2M. Beyond Ketorolac, top products include Mebendazole, Verapamil, Folic, Domperidone, Ethambutol. View the complete Cadila Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ketorolac — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ketorolac shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cadila Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 57 individual customs records matching Cadila Pharmaceuticals Limited exporting Ketorolac, covering 44 formulations to 10 countries via 16 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 124+ countries, 638+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ketorolac Export Data from Cadila Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cadila Pharmaceuticals Limited's Ketorolac exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cadila Pharmaceuticals Limited
Full Company Profile →
15 products · $20.2M total trade · 11 categories
Ketorolac Stats
Company Overview
Top Products by Cadila Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cadila Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ketorolac. For current shipment-level data, contact TransData Nexus.